Medicxi founds biotech creation engine C21Med

David Grainger and Richard Mason (Medicxi/J&J)

Medicxi has created an “ideas factory” to boost its capacity to turn early-stage science into pipelines of drug candidates and startups to develop them. The VC fund is setting up the venture with its CSO, David Grainger, Ph.D., and Johnson & Johnson’s Richard Mason, M.D. 

Anglo-Swiss investment group Medicxi made its name creating biotechs and taking them to key data readouts on lean budgets. The story of XO1, which Mason ran, exemplifies the approach. Medicxi, then called Index Ventures, created the anticoagulant biotech and led an $11 million investment in 2013. Two years later, a team consisting of two full-time staff led it to a takeover by J&J.

Medicxi has since broadened its scope, notably by adding a late-phase fund, but helping researchers turn scientific insights into drug assets remains central to its business. Setting up The Foundation Institute for 21st Century Medicine, abbreviated to C21Med, is intended to further these activities.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“It’s the same model Medicxi have been operating for a decade,” Grainger said on Twitter. “C21Med is simply an increase in scale and capacity.”

Grainger will continue to serve as CSO of Medicxi while supporting C21Med as its co-founder. The other co-founder, Mason, is currently head of J&J’s European innovation center. Grainger and Mason last worked together on XO1.

The pair are now looking to provide Medicxi with a pipeline of future successes. C21Med will filter through scientific research, latch onto the most promising ideas and put them through tests to show whether they can support a drug development program. Beyond that, Medicxi can contribute to the resulting startups' near- and potentially long-term financing needs through its two funds. 

In rolling out a late-stage fund and biotech creation engine in its two years as a standalone entity, Medicxi has bolstered its ability to found startups and equipped itself to stay with them deeper into the clinic.

Suggested Articles

By employing heart rate signals, physical activity and sleep quality, common Fitbit trackers may be able to predict the spread of the flu.

Nanox has raised $26 million to help fuel the development and commercialization of its "Star Trek"-inspired digital X-ray bed.

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.